ES2854754T3 - Tratamiento dirigido a plaquetas - Google Patents

Tratamiento dirigido a plaquetas Download PDF

Info

Publication number
ES2854754T3
ES2854754T3 ES13848463T ES13848463T ES2854754T3 ES 2854754 T3 ES2854754 T3 ES 2854754T3 ES 13848463 T ES13848463 T ES 13848463T ES 13848463 T ES13848463 T ES 13848463T ES 2854754 T3 ES2854754 T3 ES 2854754T3
Authority
ES
Spain
Prior art keywords
gene
expression
stem cell
fviii
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13848463T
Other languages
English (en)
Spanish (es)
Inventor
David Wilcox
Sandra Haberichter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Platelet Targeted Therapeutics LLC
Original Assignee
Platelet Targeted Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Platelet Targeted Therapeutics LLC filed Critical Platelet Targeted Therapeutics LLC
Application granted granted Critical
Publication of ES2854754T3 publication Critical patent/ES2854754T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES13848463T 2012-10-24 2013-10-24 Tratamiento dirigido a plaquetas Active ES2854754T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717951P 2012-10-24 2012-10-24
PCT/US2013/066651 WO2014066663A1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment

Publications (1)

Publication Number Publication Date
ES2854754T3 true ES2854754T3 (es) 2021-09-22

Family

ID=50545271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13848463T Active ES2854754T3 (es) 2012-10-24 2013-10-24 Tratamiento dirigido a plaquetas

Country Status (12)

Country Link
US (4) US9982034B2 (enExample)
EP (2) EP3859004A1 (enExample)
JP (2) JP2016501515A (enExample)
KR (1) KR101819803B1 (enExample)
BR (1) BR112015009229B1 (enExample)
CA (1) CA2888982C (enExample)
DK (1) DK2912186T3 (enExample)
ES (1) ES2854754T3 (enExample)
IL (1) IL238417B (enExample)
PL (1) PL2912186T3 (enExample)
WO (1) WO2014066663A1 (enExample)
ZA (1) ZA201502945B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
CA3087344A1 (en) 2018-01-05 2019-07-11 Platelet Biogenesis, Inc. Compositions and methods for producing megakaryocytes
JP2021529770A (ja) 2018-06-29 2021-11-04 プレートレット バイオジェネシス， インコーポレイテッド 薬物送達のための組成物およびその使用方法
WO2020072471A1 (en) * 2018-10-05 2020-04-09 University Of Utah Research Foundation Methods of making platelets comprising modified receptors and uses thereof
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. SLIDES LOADED WITH ANTI-CANCER AGENTS
WO2020186193A1 (en) * 2019-03-13 2020-09-17 Cellphire, Inc. Canine blood platelet preparations
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
US12618076B2 (en) 2019-10-01 2026-05-05 University Of Utah Research Foundation Methods of engineering platelets for targeting circulating tumor cells
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
US12702682B2 (en) 2021-11-04 2026-08-11 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2452892A (en) 1947-05-07 1948-11-02 Robert A Appleton Igniter for rockets
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE234129T1 (de) 1996-06-18 2003-03-15 Alza Corp Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
KR100453132B1 (ko) 1996-12-20 2004-10-15 앨자 코포레이션 경피 약제 플럭스를 향상시키기 위한 장치 및 방법
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CN1285753A (zh) 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
EP1048736A1 (en) * 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-construct for the tissue specific expression of a blood coagulation factor
CA2450125A1 (en) * 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
ATE527347T1 (de) * 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
KR20050048539A (ko) 2001-10-06 2005-05-24 메리얼엘엘씨 ＣｐＧ 제제 및 관련된 방법
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
JP2008518610A (ja) * 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
KR100981092B1 (ko) * 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
WO2010075303A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8147820B2 (en) 2009-09-14 2012-04-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated vaccine against fish pathogen Francisella sp
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
US20120225028A1 (en) 2011-03-02 2012-09-06 Moshe Cohen Compositions and methods for mobilization of stem cells

Also Published As

Publication number Publication date
KR20150069017A (ko) 2015-06-22
US10294291B2 (en) 2019-05-21
US20190270791A1 (en) 2019-09-05
JP6975105B2 (ja) 2021-12-01
ZA201502945B (en) 2016-11-30
EP2912186B1 (en) 2021-01-06
JP2016501515A (ja) 2016-01-21
US20240270822A1 (en) 2024-08-15
KR101819803B1 (ko) 2018-01-17
US20180009874A1 (en) 2018-01-11
US20150344541A1 (en) 2015-12-03
US9982034B2 (en) 2018-05-29
WO2014066663A1 (en) 2014-05-01
PL2912186T3 (pl) 2021-06-14
DK2912186T3 (da) 2021-02-22
IL238417A0 (en) 2015-06-30
BR112015009229B1 (pt) 2021-07-20
CA2888982C (en) 2020-07-21
IL238417B (en) 2019-07-31
BR112015009229A2 (pt) 2017-11-14
EP2912186A4 (en) 2016-06-08
JP2018161152A (ja) 2018-10-18
EP2912186A1 (en) 2015-09-02
CA2888982A1 (en) 2014-05-01
EP3859004A1 (en) 2021-08-04
HK1211986A1 (en) 2016-06-03

Similar Documents

Publication Publication Date Title
US20240270822A1 (en) Platelet targeted treatment
AU2011377617B2 (en) Improved gene therapy methods
US10022405B2 (en) IL-12 immunotherapy for cancer
ES2770627T3 (es) Vector dual para la inhibición del virus de la inmunodeficiencia humana
US20090148425A1 (en) Therapeutic method for blood coagulation disorder
JP2018519827A (ja) 逆配向のヒトユビキチンｃプロモーターを含むレトロウイルスベクター
JP2018521643A (ja) 非組み込みウイルス送達システムおよびその使用の方法
WO2022238595A1 (es) Vectores lentivirales y usos de los mismos
HK40057844A (en) Platelet targeted treatment
HK1211986B (en) Platelet targeted treatment
KR100969271B1 (ko) 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합 발현 벡터 시스템
KR100969268B1 (ko) 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합 발현 벡터 시스템
BR122025001131A2 (pt) Sequências de promotores, vetor, plasmídeo ou molécula de ácido nucleico compreendendo as referidas sequências, nanopartícula contendo polímero, e métodos relacionados
Gutiérrez-Guerrero Gene editing as an alternative to retroviral vectors for Wiskott-Aldrich syndrome gene therapy
Ide Hematopoietic stem cell mediated gene therapy for hemophilia A using high-expression factor VIII constructs
Ward Lentiviral vectors for treatment of haemophilia
HK1127549A (en) Therapeutic method for blood coagulation disorder
Abdul-Razak Correction of the classical scid mouse mutation by gene repair
Duarte 77. HIV-1 Vector Production Mediated by Rev Protein Transduction